Research programme: CSP inhibitors - ArQule

Drug Profile

Research programme: CSP inhibitors - ArQule

Alternative Names: 650 series; ARQ-650RP

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator ArQule
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 05 Jul 2006 This programme is still in active development
  • 14 Dec 2005 ArQule has filed an IND with the US FDA for Cancer
  • 31 Aug 2005 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top